The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Demonstrating preclinical efficacy of AUY922, a novel Hsp90 inhibitor, alone and in combination with standard chemotherapy or radiation in esophageal adenocarcinoma.
Juliann Kosovec
No relevant relationships to disclose
Christina Rotoloni
No relevant relationships to disclose
Ali H Zaidi
No relevant relationships to disclose
Yoshihiro Komastu
No relevant relationships to disclose
Lori Kelly
No relevant relationships to disclose
Daisuke Matsui
No relevant relationships to disclose
Amina Waheed
No relevant relationships to disclose
Toshitaka Hoppo
No relevant relationships to disclose
Blair A Jobe
No relevant relationships to disclose